The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 23, 2019
Filed:
Feb. 23, 2018
Applicant:
École Polytechnique Fédérale DE Lausanne (Epfl), Lausanne, CH;
Inventors:
Assignee:
École Polytechnique Fédérale de Lausanna (EPFL), Lusanne, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/51 (2006.01); C12N 9/82 (2006.01); C07K 7/08 (2006.01); C12N 9/96 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 47/64 (2017.01); A61K 47/68 (2017.01); A61K 9/107 (2006.01); C07K 16/18 (2006.01); C07K 14/62 (2006.01); C07K 14/74 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6811 (2017.08); A61K 9/1075 (2013.01); A61K 9/513 (2013.01); A61K 39/001 (2013.01); A61K 39/0008 (2013.01); A61K 47/64 (2017.08); A61K 47/6803 (2017.08); A61K 47/6815 (2017.08); A61K 47/6843 (2017.08); A61K 47/6849 (2017.08); C07K 7/08 (2013.01); C07K 14/62 (2013.01); C07K 14/70539 (2013.01); C07K 16/18 (2013.01); C07K 16/28 (2013.01); C12N 9/82 (2013.01); C12N 9/96 (2013.01); C12Y 305/01001 (2013.01); A61K 38/00 (2013.01); A61K 2039/605 (2013.01); A61K 2039/6031 (2013.01); A61K 2039/6056 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01); C07K 2319/21 (2013.01); C07K 2319/22 (2013.01); C07K 2319/23 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C07K 2319/41 (2013.01); C07K 2319/43 (2013.01); C07K 2319/74 (2013.01);
Abstract
Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.